Olumiant (baricitinib) is a once-daily oral JAK inhibitor licensed for rheumatoid arthritis, atopic dermatitis, severe alopecia areata and juvenile idiopathic arthritis, and its labelled doses differ by region, so the strength mix you order depends on the label of the market you ship to.
M Care Exports supplies Olumiant (baricitinib), the Eli Lilly originator brand, as 1 mg, 2 mg and 4 mg film-coated tablets for hospital pharmacies, tender desks and licensed importers. Olumiant is a Janus kinase (JAK) inhibitor taken once daily by mouth, with no injection and no cold chain. M Care is a merchant-exporter: we source the originator pack through licensed channels and quote per destination, not from our own manufacturing.
Baricitinib exporter and bulk supplier from India.
"I'm looking for Olumiant 4 mg and 2 mg for a tender" is the enquiry we see most. M Care Exports answers it with a quote built on the buyer's specification: strength (1 mg, 2 mg or 4 mg), pack size, quantity, the destination regulator's registration route and the dossier or Certificate of Pharmaceutical Product paperwork it expects. We confirm the pack presentation at quotation, because the US presentation (one bottle of 30 tablets per strength) and the European and UK presentation (aluminium blister cartons of 14 to 98 tablets, not every size marketed) are different packs, and a registered market usually accepts only the one on its file. Tell us the label your regulator holds and we match supply to it.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Janus kinase (JAK) inhibitor, sourced and documented for export.
Baricitinib is a selective JAK inhibitor given once daily as a film-coated tablet. The US label lists 1 mg (very light pink, round), 2 mg (light pink, oblong) and 4 mg (medium pink, round) tablets, debossed Lilly. The UK SmPC lists 2 mg and 4 mg. The US label lists rheumatoid arthritis after inadequate response to one or more TNF blockers, hospitalised adults with COVID-19 needing oxygen or ventilatory support, and severe alopecia areata in adults and patients aged 12 and over. The EMA lists moderate to severe rheumatoid arthritis, atopic dermatitis from age 2, severe alopecia areata from age 12 and juvenile idiopathic arthritis from age 2; the UK SmPC (July 2024 version) limits alopecia areata to adults. US storage is 20 to 25 C with excursions permitted to 15 to 30 C. The UK SmPC gives a 3-year shelf life and no special storage conditions. The US label carries a boxed warning for serious infections including tuberculosis, mortality, malignancy, major adverse cardiovascular events and thrombosis.
Active ingredient
Baricitinib. Janus kinase (JAK) inhibitor.
Forms and strengths
1 mg film-coated tablet; 2 mg film-coated tablet; 4 mg film-coated tablet.
Indications
Baricitinib is a Janus kinase inhibitor taken orally once daily, licensed for rheumatoid arthritis, atopic dermatitis, severe alopecia areata and juvenile idiopathic arthritis depending on the market, marketed as Olumiant by Eli Lilly.
Administration
Oral. Film-coated tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
We supply hospital pharmacies, ministry of health and hospital tender desks, licensed importers and distributors in the GCC, Africa and the UK. A typical enquiry is "We need a partner for Olumiant" from an importer who holds the registration or is preparing it. Because Olumiant is a prescription-only immunology and dermatology medicine, buyers are usually hospital and specialty pharmacies rather than general retail. Saudi Arabia is a useful GCC reference point: the SFDA hosts Olumiant healthcare professional educational material, with a 2026 version published. For the UAE and Nigeria, we could not confirm registration status from a regulator page, so confirm the product's status with the EDE in the UAE or NAFDAC in Nigeria for your pack before committing volume.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on baricitinib.
Dosing differs by label, which matters when you set strengths. The US label starts rheumatoid arthritis at 2 mg once daily, and for severe alopecia areata starts at 2 mg, increasing to 4 mg if response is inadequate, with 4 mg considered from the start for nearly complete or complete scalp hair loss. The UK SmPC gives 4 mg once daily for rheumatoid arthritis, atopic dermatitis and alopecia areata in adults, with 2 mg for patients aged 65 or over, those at higher risk of VTE, MACE or malignancy, and those with a history of chronic or recurrent infections. Renal function drives strength: in the US label for rheumatoid arthritis, eGFR 30 to under 60 takes 1 mg and eGFR under 30 is not recommended; the UK SmPC gives 2 mg at creatinine clearance 30 to 60 mL/min and does not recommend use below 30. Strong OAT3 inhibitors such as probenecid call for a one-step dose reduction in the US label. Treatment is interrupted for low lymphocyte, neutrophil or haemoglobin counts per the label thresholds. The US label does not recommend use in severe hepatic impairment (Child-Pugh C) for rheumatoid arthritis and alopecia areata.
The documentation pack a regulator actually asks for.
Olumiant needs no cold chain, which separates it from the biologics it competes with. The UK SmPC states no special storage conditions and a 3-year shelf life; the US label requires 20 to 25 C. We dispatch on standard ambient lanes with batch-level documentation: certificate of analysis, batch number and expiry. The original brand holder is Eli Lilly: Eli Lilly Nederland B.V. is the EU marketing authorisation holder, with authorisation dated 13 February 2017. In the UK the emc page now shows Olumiant as discontinued, stating the medicine will now be known as Baricitinib Lilly film-coated tablets, so UK-bound enquiries should say which name the importer's authorisation uses. M Care does not hold manufacturing or WHO-GMP status for this product; we are a merchant-exporter and supply the originator pack through licensed channels.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside baricitinib.
Tacrolimus
Topical calcineurin inhibitor · atopic dermatitis (eczema)
Risankizumab
IL-23 antagonist · psoriasis, PsA, Crohn's disease, ulcerative colitis
Dupilumab
IL-4/IL-13 blocker · atopic dermatitis, asthma
Upadacitinib
Rinvoq · JAK inhibitor for RA, PsA, atopic dermatitis and IBD
All allergy & immunology
The full category listing for procurement desks.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for baricitinib.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Baricitinib supply, the specific questions.
What is Olumiant used for?
Olumiant (baricitinib) is a once-daily oral JAK inhibitor. The EMA lists moderate to severe rheumatoid arthritis, moderate to severe atopic dermatitis (adults and children from 2 years), severe alopecia areata (adults and adolescents from 12 years) and active juvenile idiopathic arthritis (from 2 years). The US label lists rheumatoid arthritis after inadequate response to TNF blockers, hospitalised COVID-19 requiring oxygen or ventilatory support, and severe alopecia areata in adults and patients aged 12 and over. Indications differ by market, so quote against your regulator's label.
Olumiant 4 mg or 2 mg: which strength do I order?
It depends on the label of the destination. The UK SmPC uses 4 mg once daily for adults with rheumatoid arthritis, atopic dermatitis and alopecia areata, with 2 mg for patients aged 65 or over, higher-risk patients, those with chronic or recurrent infections and those with creatinine clearance of 30 to 60 mL/min. The US label starts rheumatoid arthritis at 2 mg and alopecia areata at 2 mg, rising to 4 mg if response is inadequate. The US label also lists a 1 mg tablet for renal dose reduction; the UK SmPC lists only 2 mg and 4 mg. We quote all three strengths and match the pack your registration lists.
Is Olumiant licensed for hair loss, and how does alopecia areata dosing work?
The labels we reviewed list severe alopecia areata only, and not other types of hair loss. The US label covers adults and patients aged 12 and over, starts at 2 mg once daily, increases to 4 mg if response is inadequate, and reduces to 2 mg once adequate response is achieved. The EMA lists adults and adolescents from 12 years, while the UK SmPC (July 2024 version) lists adults only and suggests considering stopping if there is no benefit after 36 weeks. Pharmacies should dispense against a prescription.
What is the price of Olumiant 4 mg, for example in the UAE?
We do not publish a price. The landed price for an importer depends on whether you want the originator or a generic, the pack and strength, the quantity, the destination's registration route, any documentation needs, and Incoterms (EXW, CIF or DDP). Olumiant needs no cold chain, so there is no refrigerated freight line. M Care Exports quotes per destination, so send us the country, strength, pack and annual volume and we will respond with a written quotation.
Is there a generic baricitinib, and where?
The US label and EMA page we fetched list Olumiant from Eli Lilly, and we did not find a generic baricitinib in either source. For GCC, African or UK tenders, we confirm whether the buyer's registration is for the originator or a generic before quoting.
Does Olumiant need cold chain, and does the UK name differ?
No cold chain is needed. The UK SmPC says no special storage conditions and a 3-year shelf life, and the US label requires 20 to 25 C. In the UK, the emc entry for Olumiant is marked discontinued and states the medicine will now be known as Baricitinib Lilly film-coated tablets. A UK importer should tell us which name its authorisation carries so the pack and paperwork match.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-11-07.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.